Loading...
XNAS
SBFM
Market cap7mUSD
Dec 04, Last price  
1.44USD
1D
-1.37%
1Q
6.27%
Jan 2017
-99.99%
IPO
-100.00%
Name

Sunshine Biopharma Inc

Chart & Performance

D1W1MN
XNAS:SBFM chart
P/E
P/S
0.20
EPS
Div Yield, %
Shrs. gr., 5y
231.05%
Rev. gr., 5y
340.11%
Revenues
35m
+44.75%
000000001,70800447,20021,12171,410228,4264,345,60324,092,78734,874,000
Net income
-5m
L+13.94%
-13,122-31,1050-537,382-556,202-707,952-2,491,483-1,934,210-1,652,908-3,496,687-1,040,236-2,156,155-1,461,440-897,683-12,765,265-26,744,440-4,506,044-5,134,000
CFO
-13m
L+42.80%
-3,122-27,533-10,225-348,325-297,299-393,054-564,398-538,595-867,644-314,182-543,520-512,806-495,798-657,299-1,829,128-5,248,358-8,775,111-12,531,180

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
IPO date
Aug 15, 2008
Employees
46
Domiciled in
CA
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT